Building a Better Understanding of the Intracellular Tyrosine Kinase PTK6 - BRK by BRK

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2010 Mar 3

PMID 20193745

Citations 57

Authors

Patrick M Brauer

Angela L Tyner

Affiliations

Soon will be listed here.

Abstract

Protein tyrosine kinase 6 (PTK6), also referred to as breast tumor kinase BRK, is a member of a distinct family of kinases that is evolutionarily related to the SRC family of tyrosine kinases. While not expressed in the normal mammary gland, PTK6 expression is detected in a large proportion of human mammary gland tumors. In breast tumor cells, PTK6 promotes growth factor signaling and cell migration. PTK6 expression is also increased in a number of other epithelial tumors, including ovarian and colon cancer. In contrast, PTK6 is expressed in diverse normal epithelia, including the linings of the gastrointestinal tract, skin and prostate, where its expression correlates with cell cycle exit and differentiation. Disruption of the mouse Ptk6 gene leads to increased growth and impaired differentiation in the small intestine that is accompanied by increased AKT and Wnt signaling. Following total body irradiation, PTK6 expression is induced in proliferating progenitor cells of the intestine, where it plays an essential role in DNA-damage induced apoptosis. A distinguishing feature of PTK6 is its flexibility in intracellular localization, due to a lack of amino-terminal myristoylation/palmitoylation. Recently a number of substrates of PTK6 have been identified, including nuclear RNA-binding proteins and transcription factors. We discuss PTK6 signaling, its apparent conflicting roles in cancer and normal epithelia, and its potential as a therapeutic target in epithelial cancers.

Citing Articles

Identification of immune-associated biomarker for predicting lung adenocarcinoma: bioinformatics analysis and experiment verification of PTK6.

Xiong R, Yang S, Li J, Shen X, Jin L, Chen C Discov Oncol. 2024; 15(1):102.

PMID: 38573548 PMC: 10994900. DOI: 10.1007/s12672-024-00939-9.

In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking.

Zhou Y, Wong M Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256893 PMC: 10818313. DOI: 10.3390/ph17010060.

Comprehensive review of α-carboline alkaloids: Natural products, updated synthesis, and biological activities.

Li D, Yang R, Wu J, Zhong B, Li Y Front Chem. 2022; 10:988327.

PMID: 36092663 PMC: 9459053. DOI: 10.3389/fchem.2022.988327.

Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.

Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T Cells. 2022; 11(16).

PMID: 36010693 PMC: 9406645. DOI: 10.3390/cells11162618.

Src Family Kinases: A Potential Therapeutic Target for Acute Kidney Injury.

Li N, Lin G, Zhang H, Sun J, Gui M, Liu Y Biomolecules. 2022; 12(7).

PMID: 35883540 PMC: 9312434. DOI: 10.3390/biom12070984.

References

Aubele M, Vidojkovic S, Braselmann H, Ritterswurden D, Auer G, Atkinson M . Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification. Virchows Arch. 2009; 455(2):117-23. DOI: 10.1007/s00428-009-0809-8. View

Ostrander J, Daniel A, Lofgren K, Kleer C, Lange C . Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res. 2007; 67(9):4199-209. DOI: 10.1158/0008-5472.CAN-06-3409. View

Kim H, Lee S . An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6. J Biol Chem. 2005; 280(32):28973-80. DOI: 10.1074/jbc.M504568200. View

Coldren C, Helfrich B, Witta S, Sugita M, Lapadat R, Zeng C . Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006; 4(8):521-8. DOI: 10.1158/1541-7786.MCR-06-0095. View

Lukong K, Richard S . Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. Cell Signal. 2007; 20(2):432-42. DOI: 10.1016/j.cellsig.2007.11.003. View

Harvey A, Crompton M . Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene. 2003; 22(32):5006-10. DOI: 10.1038/sj.onc.1206577. View

Uckun F, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C . Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2006; 15(2):800-14. DOI: 10.1016/j.bmc.2006.10.050. View

Haegebarth A, Heap D, Bie W, Derry J, Richard S, Tyner A . The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem. 2004; 279(52):54398-404. DOI: 10.1074/jbc.M409579200. View

Qiu H, Zappacosta F, Su W, Annan R, Miller W . Interaction between Brk kinase and insulin receptor substrate-4. Oncogene. 2005; 24(36):5656-64. DOI: 10.1038/sj.onc.1208721. View

10.

Qiu H, Miller W . Role of the Brk SH3 domain in substrate recognition. Oncogene. 2003; 23(12):2216-23. DOI: 10.1038/sj.onc.1207339. View

11.

Meric F, Lee W, Sahin A, Zhang H, Kung H, Hung M . Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 2002; 8(2):361-7. View

12.

Hong E, Shin J, Bang E, Kim M, Lee S, Lee W . Complete sequence-specific 1H, 13C and 15N resonance assignments of the human PTK6 SH2 domain. J Biomol NMR. 2001; 19(3):291-2. DOI: 10.1023/a:1011221125013. View

13.

Madson J, Lynch D, Tinkum K, Putta S, Hansen L . Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation. Am J Pathol. 2006; 169(4):1402-14. PMC: 1780187. DOI: 10.2353/ajpath.2006.060082. View

14.

Nahta R, Esteva F . Trastuzumab: triumphs and tribulations. Oncogene. 2007; 26(25):3637-43. DOI: 10.1038/sj.onc.1210379. View

15.

Mitchell P, Barker K, Martindale J, Kamalati T, Lowe P, Page M . Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene. 1994; 9(8):2383-90. View

16.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

17.

Lukong K, Larocque D, Tyner A, Richard S . Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem. 2005; 280(46):38639-47. DOI: 10.1074/jbc.M505802200. View

18.

Mitchell P, Sara E, Crompton M . A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene. 2000; 19(37):4273-82. DOI: 10.1038/sj.onc.1203775. View

19.

Kim H, Lee S . Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. J Biochem. 2009; 146(1):133-9. DOI: 10.1093/jb/mvp050. View

20.

Groner B, Lucks P, Borghouts C . The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol. 2008; 19(4):341-50. DOI: 10.1016/j.semcdb.2008.06.005. View